Mancini Anthony's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Apr 29, 2026
- Accession no.
- 0001610717-26-000158
- Filed
- Apr 29, 2026
- Trade date
- Apr 27, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $413.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mancini AnthonyCIK 0002124509 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Common Stock | MOption exerciseAcquired | +3,120 | $33.62 | +$104,894.4 | 57,520 | Direct | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −1,671 | $131.66F3 | −$220,003.86 | 55,849 | Direct | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −1,049 | $132.88F4 | −$139,391.12 | 54,800 | Direct | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −400 | $134.34F5 | −$53,736 | 54,400 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Common Stock | MOption exerciseDisposed | −3,120 | $0.00 | $0 | 109,230 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $131.08 to $132.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $132.37 to $133.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $134.04 to $134.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Global Commercialization Officer